|1.||Enjalbert, A: 2 articles (01/2001 - 02/2000)|
|2.||Jaquet, P: 2 articles (01/2001 - 02/2000)|
|3.||Gunz, G: 2 articles (01/2001 - 02/2000)|
|4.||Fina, F: 2 articles (01/2001 - 02/2000)|
|5.||Culler, M D: 2 articles (01/2001 - 02/2000)|
|6.||Saveanu, A: 2 articles (01/2001 - 02/2000)|
|7.||Moreau, J P: 2 articles (01/2001 - 02/2000)|
|8.||Cap, J: 1 article (06/2003)|
|9.||Suba, P: 1 article (06/2003)|
|10.||Marek, J: 1 article (06/2003)|
01/01/2001 - "In these tumors the suppression of GH release was similarly achieved at picomolar ranges by octreotide, BIM-23197, and BIM-23244 (EC(50) = 25 +/- 15, 3 +/- 2, and 3 +/- 3 pmol/L, respectively). "
04/01/1998 - "Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer."
02/01/2000 - "In the present study the quantitative expression of messenger ribonucleic acid (mRNA) for the 5 SSTR subtypes and the inhibitory effects of SRIF14; SRIF28; octreotide; the SSTR2-preferential analog, BIM-23197; and the SSTR5-preferential analog, BIM-23268, on GH and PRL secretion were analyzed in cells cultured from 15 acromegalic tumors. "
09/01/1999 - "The present study examines the quantitative profile of SSTRs messenger ribonucleic acid (mRNA) in 10 PRL-secreting tumors and correlates the expression with the ability of native somatostatins (SS14 and SS28), SSTR2 preferential analogs (octreotide and BIM-23197), and the SSTR5 preferential analog BIM-23268 to suppress PRL secretion. "
01/01/2001 - "In the present study we quantified SSTR2 and SSTR5 mRNA expression and the GH-suppressive effects of somatostatin-14; octreotide; a SSTR2-preferential compound, BIM-23197; a SSTR5-preferential compound, BIM-23268; and a new SSTR2- and SSTR5-bispecific compound, BIM-23244, in GH-secreting tumors classified as either full responders to octreotide (n = 5) or partially sensitive to octreotide (n = 5). "
06/01/2003 - "2. The GH secretion in six adenomas was suppressed significantly more (p < 0.01 or p < 0.001 using Mann-Whitney U-test in concentration range of 10(-12) to 10(-8) mol/l) with SSTR2 specific analogue BIM-23197 with no additive effect of compounds combination. "
06/01/2003 - "3. In three adenomas the potency of BIM-23197 and BIM-23268 was almost equal and the combination of these SSTR2 and SSTR5 specific compounds had statistically significant additive effect (p < 0.05 or p < 0.01 in concentration range of 10(-12) to 10(-8) mol/l). "
02/01/2000 - "In cells cultured from adenomas taken from patients partially responsive to the SRIF analog, octreotide, partial additivity in suppressing both GH and PRL secretion was observed when the SSTR2- and SSTR5-preferring analogs, BIM-23197 and BIM-23268, were tested in combination. "
|3.||Messenger RNA (mRNA)
|4.||RNA (Ribonucleic Acid)
|6.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|8.||tranilast (N 5')